Calcium Signaling Silencing in Atrial Fibrillation: Implications for Atrial Sodium Homeostasis

Area of Science:

• Cardiology
• Molecular Biology
• Electrophysiology

Background:

• Atrial fibrillation (AF) is a prevalent cardiac arrhythmia with high recurrence rates despite advances in treatment.
• Intracellular calcium (Ca2+) handling is significantly altered in AF, with both arrhythmogenic and protective mechanisms observed.
• Intracellular sodium ([Na+]) is a critical regulator of Ca2+ handling, yet its role in AF remains poorly understood.

Purpose of the Study:

• To review alterations in intracellular Na+ homeostasis during AF.
• To summarize proposed arrhythmogenic mechanisms linked to increased atrial sodium current (INa,L) in AF.
• To discuss clinical trial evidence for INa,L blockers, such as ranolazine, in AF treatment.

Main Methods:

• Literature review of cellular and molecular changes in AF.
• Analysis of research on intracellular Ca2+ and Na+ handling in cardiac myocytes.
• Examination of studies investigating the atrial sodium current (INa,L) in AF.
• Review of clinical trial data on ranolazine for AF treatment.

Main Results:

• AF is associated with complex changes in intracellular Ca2+ handling, including "Calcium Signaling Silencing."
• Evidence suggests elevated intracellular Na+ and increased INa,L may contribute to AF.
• Pharmacological blockade of INa,L is being investigated as a therapeutic strategy for AF.

Conclusions:

• Understanding Na+ dysregulation in AF is crucial for identifying novel therapeutic targets.
• Targeting INa,L represents a promising strategy for managing AF.
• Ranolazine's efficacy in clinical trials warrants further investigation for AF treatment.